Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIOYF/RX.V has really been moving since it was added to the portfolio less than a week ago. It is up 20% so far.
MTY Food Group – A Case Study of a 100-Bagger
http://microcapclub.com/2015/03/mty-food-group-a-case-study-of-a-100-bagger/
Ian Cassel and I created a two part radio program entitled "So You Want To Be A Full Time MicroCap Investor?" It should be helpful to investors even if they don't want to go full time. Enjoy!
http://microcapclub.com/2015/01/so-you-want-to-be-a-full-time-microcap-investor/
http://microcapclub.com/2015/02/so-you-want-to-be-a-full-time-microcap-investor-part-2/
Cemtrex (OTC: CTEI) Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Exchange
FARMINGDALE, N.Y., April 14, 2015 /PRNewswire/ -- Cemtrex Inc. (www.cemtrex.com) announced today that in preparation for its planned uplisting to the NASDAQ CM Exchange, it is effecting a 1 for 6 reverse stock split of its common stock, to be effective for trading purposes as of the commencement of trading on April 15th, 2015. As of this date, every six (6) shares of issued and outstanding common stock will be converted into one (1) share of common stock.
Photo - http://photos.prnewswire.com/prnh/20150413/198208LOGO
As of the market open on April 15th, the common stock will be trading under a new CUSIP number (15130G303), although the Company's ticker symbol, CTEI, will remain unchanged. However, the company's shares of common stock will trade on the OTCQC Marketplace under symbol, "CTEID", with the "D" added for the next 20 trading days to signify the stock split.
"Many of our shareholders and investors have supported our interest in moving Cemtrex to the NASDAQ Capital Markets exchange," said Saagar Govil, Chairman and Chief Executive Officer of Cemtrex. He continued, "We view this reverse split as one of the last remaining steps in meeting the requirements to be on the exchange and are working to get this important company milestone completed swiftly. Uplisting to a major exchange like NASDAQ will better enable us to attract a broader range of institutional investors and increase share liquidity."
As a result of the Reverse Split, the total issued and outstanding common shares will be reduced from approximately 40.7 million shares to approximately 6.8 million, subject to adjustment for fractional shares. No fractional shares will be issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
Stockholders who hold their shares in brokerage accounts or "street name" will have their shares automatically adjusted to reflect the reverse stock split. Holders of share certificates will receive instructions from the company's transfer agent, First American Stock Transfer, Inc. with specific instructions regarding the exchange of shares. Stockholders should direct any questions concerning the Reverse Split to their broker or the Company's transfer agent, First American Stock Transfer, (602) 485-1346.
About Cemtrex, Inc.
Cemtrex, Inc. (OTC: CTEI) is a diversified technology company that provides a wide array of solutions to meet today's industrial challenges. Cemtrex, through its wholly owned subsidiaries provides electronic manufacturing services of custom engineered printed circuit board assemblies, emission monitors & instruments for industrial processes, and environmental control & air filtration systems for industries & utilities.
www.cemtrex.com
Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.
For further information, please contact:
Investor Relations
Cemtrex, Inc.
Phone: 631-756-9116
Email
Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
Company Stock to Commence Trading on NASDAQ on April 16, 2015, Under
NORWOOD, MA--(Marketwired - Apr 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab,™ for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that the NASDAQ Stock Market LLC has approved the Company's application to have its common stock listed on The NASDAQ Capital Market (NASDAQ). The stock will commence trading on The NASDAQ Capital Market on April 16, 2015, under its existing ticker symbol CRBP.
"Becoming a NASDAQ-listed company marks an important milestone for Corbus and reflects the hard work and dedication of our management team to build a strong, innovative, clinical stage biotech company," commented Sean Moran, CPA, MBA, Chief Financial Officer of Corbus Pharmaceuticals. "We believe that trading on NASDAQ will serve to raise the visibility of Corbus, enhance trading liquidity and broaden our shareholder base as we initiate our upcoming clinical studies with Resunab."
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, added, "Last month we achieved an important regulatory milestone having received clearance for our Investigational New Drug (IND) application for Resunab from the U.S. Food and Drug Administration. This IND enables us to proceed as planned with the initiation of our Phase 2 clinical study in diffuse cutaneous systemic sclerosis (scleroderma) and the submission of a Phase 2 protocol for the treatment of cystic fibrosis in the second quarter of 2015."
About Resunab™
Resunab™ is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 clinical studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."
About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate, Resunab™, is a novel oral specialized pro-resolving mediator anti-inflammatory drug scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Investor Contact
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: Email Contact
Media Contact
David Schull or Marissa Goberdhan
Russo Partners, LLC
Phone: +1 (858) 717-2310
Email: Email Contact or Email Contact
The WLDN ascent continues.
Buy 300 shares of BIOYF/RX.V for the SwingTrade Portfolio for $5.85.
Here is my EACO DD which I posted on MicroCapClub over the weekend.
EACO Corporation, through its wholly-owned subsidiary, Bisco Industries, Inc., distributes and sells electronic components and fasteners in the United States and Canada. You can learn more about Bisco here:
https://www.biscoind.com/
They also have two more brands that they operate under called National Precision and Fast-Cor as mentioned on their corporate web site which is located here:
http://www.eacocorp.com/
They have a nice video on the Bisco web site which gives you a background on the company. Here is the video:
Year Ending Aug 31st Revenue EPS
2014 $134.747M * $1.14
2013 $120.432M $0.51
2012 $114.634M $0.48
2011 $103.467M $0.42
2010 $91.547M -$0.30
WLDN is surging ahead. The last print was at $14.98.
Eco-Stim Energy Solutions Announces Approval for Listing on NASDAQ
HOUSTON and NEUQUEN CITY, Argentina, April 6, 2015 (GLOBE NEWSWIRE) -- Eco-Stim Energy Solutions, Inc. (ESES) ("EcoStim" or the "Company") announced today that it has received confirmation that its application to list the company's common stock on the NASDAQ Capital Market has been approved by The NASDAQ Stock Market, a unit of the NASDAQ OMX Group.
EcoStim's common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on April 10, 2015 under the ticker symbol, ESES. The Company's common stock will continue to trade on the Over-the-Counter Bulletin Board until the market close on April 9, 2015 under the ticker symbol, ESES.
J. Chris Boswell, CEO of EcoStim stated, "Our listing on the NASDAQ is a major milestone for EcoStim and a testament to the tremendous progress we have made over the past year. We believe that the NASDAQ listing will help broaden our shareholder base and provide better liquidity for all shareholders. We continue to believe that the emerging shale oil and gas basins around the world, and in particular the Vaca Muerta shale play in Argentina, offer investors a unique growth opportunity."
EcoStim has established a meaningful presence in this region, offering well stimulation, coiled tubing, and field management services to an expanding customer base in Argentina. This technology platform offers customers an approach that reduces the ecological impact on communities while at the same time reducing cost.
Boswell went on to say, "We feel our approach is especially important in lower commodity price environments as operators focus on more economical and ecological solutions to their drilling and completion programs. However, in Argentina where oil and gas prices are substantially above the prices being realized in the US and other parts of the world, the oil and gas development activity level remains strong which offers those companies participating in the local market the opportunity to grow. At EcoStim, we will continue to identify other undersupplied regions of the world where we can offer our technology and services while creating shareholder value."
About the Company
Eco-Stim Energy Solutions is an environmentally focused oilfield service and technology company providing proprietary field management technologies and well stimulation and completion services to oil and gas producers drilling in the rapidly expanding international unconventional shale market. EcoStim's proprietary methodology and technology offers the potential to decrease the number of stages stimulated in shale plays through a unique process that predicts high probability production zones while confirming those production zones using the latest generation down-hole diagnostic tools. In addition, EcoStim offers its clients completion techniques that can dramatically reduce horsepower requirements, emissions, surface footprint and water usage. EcoStim seeks to deliver well completion services with better technology, better ecology and significantly improved economics for unconventional oil and gas producers worldwide.
Forward-Looking Statements:
The foregoing contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management's experience, expectations and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of performance. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contact:
Jeffrey Freedman, Investor Relations
investorrelations@ecostim-es.com
281-531-7200
Omni-Lite sees quarterly revenue and production growth as key programs continue
- Revenues increase by 29%
- Production output increases 37%
- Omni-Lite adds new aerospace customer
- New contracts announced
CERRITOS, CA, April 2, 2015 /CNW/ - Omni-Lite Industries Canada Inc. (the "Company") (OML.V) is pleased to note that it has received new contracts in the amount of $763,248 US ($969,325 CAD). Of these orders, approximately 56% are in the Aerospace division, 40% are in the Specialty Automotive division and 4% are in the Sports and Recreation division.
The Company's revenues in the first quarter of 2015 were approximately $1,774,340 US ($2,253,411 CAD). In US dollar terms, this represents an increase of approximately 29% over the revenues in the first quarter of 2014. In Canadian dollar terms, these revenues are a record for the Company's performance in the first quarter. "As a US based company, with US denominated revenues, Omni-Lite is benefiting from the continuing depreciation in the Canadian dollar versus the US currency," stated Tim Wang, CFO. "Not only are our Canadian expenses reduced in US dollar terms but our financial metrics expressed in Canadian dollars should show an upward trend."
In the first quarter, the Company's production volumes increased by approximately 37% due to increased requirements from several key customers. Of particular significance, military sales grew from a very small base to become 32% of sales in the quarter.
"The Company has received an initial order from the new aerospace customer that was mentioned in the press release of Feb 18, 2015. The Company has also been working on several new products for existing customers in the aerospace industry, with some of these components already going into full production," stated Michael Walker, VP of R and D. "With the aerospace industry continuing robust expansion, it is expected that Omni-Lite will continue to see growth in this area."
Omni-Lite is a rapidly growing high technology company that develops and manufactures precision components utilized by several Fortune 500 Companies including Boeing, Airbus, Embraer, Bombardier, Alcoa, Ford, Borg Warner, Chrysler, the U.S. Military, Nike, and adidas.
Reader Advisory
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to, the expected future performance of the Company. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in Canada, the United States and globally; industry conditions, governmental regulation, including environmental regulation; unanticipated operating events or performance; failure to obtain industry partner and other third party consents and approvals, if and when required; the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; competition for, among other things, capital, skilled personnel and supplies; changes in tax laws; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The stocks added to the portfolio yesterday were EACO, USNU, CSTI, and WLDN. Also, we purchased CTIG on Tuesday and TIK today and on Friday
Buy 300 shares of TIK at $6.64 for the SwingTrade Portfolio.
Tel-Instrument Electronics Corp. Announces 43% Increase in Fourth Quarter Revenue to $6.44 Million
Tel-Instrument Electronics Corp (“Tel”, “Tel-Instrument” or the “Company”) (NYSE MKT:TIK) today reported unaudited revenues of $6.44 million for the fiscal fourth quarter ending March 31, 2015. This represents record revenues for Tel and is a 43% increase from the year ago period. Unaudited annual revenues increased to $18.2 million, a 15% increase from year ago levels.
Jeff O’Hara, Tel’s President and CEO, stated, “This continues the steady momentum we have achieved during this fiscal year with revenues increasing sequentially each quarter. This substantial revenue increase is expected to result in solid bottom line profitability for the quarter. The Company will provide revenue guidance on the first fiscal quarter in the early May timeframe when more information on the timing of the U.S. Army TS-4530A SET production release is expected to be available.”
Tel expects to announce its full fiscal year results by June 30, 2015.
About Tel-Instrument Electronics Corp
Tel-Instrument is a leading designer and manufacturer of avionics test and measurement solutions for the global commercial air transport, general aviation, and government/military aerospace and defense markets. Tel-Instrument provides instruments to test, measure, calibrate, and repair a wide range of airborne navigation and communication equipment. For further information please visit our website at www.telinstrument.com.
This press release includes statements that are not historical in nature and may be characterized as “forward-looking statements,” including those related to future financial and operating results, benefits, and synergies of the combined companies, statements concerning the Company’s outlook, pricing trends, and forces within the industry, the completion dates of capital projects, expected sales growth, cost reduction strategies, and their results, long-term goals of the Company and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. All predictions as to future results contain a measure of uncertainty and, accordingly, actual results could differ materially. Among the factors which could cause a difference are: changes in the general economy; changes in demand for the Company’s products or in the cost and availability of its raw materials; the actions of its competitors; the success of our customers; technological change; changes in employee relations; government regulations; litigation, including its inherent uncertainty; difficulties in plant operations and materials; transportation, environmental matters; and other unforeseen circumstances. A number of these factors are discussed in the Company’s previous filings with the U.S. Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 (the “Act”) protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
Contact:
Tel-Instrument Electronics Corp.
Joseph P. Macaluso, 201-933-1600
or
Institutional Marketing Services (IMS)
John Nesbett or Jennifer Belodeau
203-972-9200
jnesbett@institutionalms.com
You should know that SSKILLZ1, MikeDDKing, Rawnoc, and BRIG_88 are the same person.
On USNU the earnings are just for three quarters so they should be able to produce around $0.09/share on an annual basis. However, I think earnings are going to grow going forward. I'll post more on that when I get around to it.
I purchased a bunch of shares today.
OK. Carry on then... :)
It is pretty quiet in here for posting four new picks. As far as I know we have never picked four new companies in one day. Is everyone in shock?
There have been no April Fools jokes in my posts.
I purchased some PFHO today.
Buy 100 shares of WLDN for $14.20 for the SwingTrade Portfolio.
I think I'm out of retirement now. :)
Buy 200 shares of CSTI for the SwingTrade Portfolio at $13.70.
Buy 3000 USNU for the SwingTrade Portfolio at $0.50.
Buy 300 shares of EACO for the SwingTrade Portfolio at $6.40.
PFHO CEO Tom Kubota purchased 300 shares of PFHO at $30.99 today.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10600615-1095-9022&type=sect&TabIndex=2&companyid=169229&ppu=%252fdefault.aspx%253fcik%253d1138476
I was also buying some CTIG at the open.
CTIG reported Q4 earnings of $0.055/share and is optimistic for the future. See the PR for commentary:
http://finance.yahoo.com/news/cti-group-reports-2014-financial-211145797.html
Buy 5000 shares of CTIG for the SwingTrade Portfolio at $0.41.
Buy 300 shares of TIK at $6.03 for the SwingTrade Portfolio.
I'm not shoveling. I'm just going to wait for it to melt.
We are probably in the 2-3" ballpark.
That was what the etc. was for.
Sell 100 shares of MUEL for the SwingTrade Portfolio at $35.75.
The report was disappointing. Earnings were down, backlog dropped, etc.
Not much has changed. It still is a great place to make money as long as one goes after real companies with revenue and earnings.
I'm doing well. I hope everything is great with you.
Welcome back.
Sell 4000 shares of ETCIA for the SwingTrade Portfolio at $0.06. Q4 was not good and the outlook is very bad.